Cuthbert J A, Lipsky P E
Proc Natl Acad Sci U S A. 1984 Jul;81(14):4539-43. doi: 10.1073/pnas.81.14.4539.
The role of low density lipoprotein (LDL) receptors in mediating the immunomodulatory effects of LDL was examined by comparing responses of normal lymphocytes with those obtained from a patient with familial hypercholesterolemia (FH) lacking receptors for LDL. The function of LDL receptors in supporting lymphocyte growth was demonstrated by blocking endogenous sterol synthesis with mevinolin, a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, and culturing cells in lipoprotein-deficient medium with supplemental LDL as the only source of cholesterol. Mevinolin inhibited mitogen-induced proliferation of normal and FH lymphocytes. Whereas inhibition was overcome by mevalonate, the product of the inhibited enzyme, low concentrations of LDL (less than 10 micrograms of protein/ml) restored the responses of normal but not FH lymphocytes. When normal and FH lymphocytes were cultured in the absence of mevinolin, high concentrations of LDL (greater than 100 micrograms of protein/ml) inhibited mitogen-induced lymphocyte proliferation. The inhibitory effects on normal and FH lymphocytes were similar in that both required comparably large concentrations of LDL and could be completely reversed by transferrin. When normal lymphocytes were cultured in serum-free medium supplemented with transferrin, low concentrations of LDL (less than 10 micrograms of protein/ml) caused marked augmentation of proliferation. By contrast, no enhancement of FH lymphocyte growth was observed. These results indicate that LDL-mediated enhancement of lymphocyte growth in the presence or absence of endogenous sterol biosynthesis involves specific receptors for LDL whereas the immunosuppression caused by LDL is independent of these receptors. Moreover, the results suggest that peripheral lymphocytes can be used to evaluate the functional integrity of the receptor-mediated uptake of LDL.
通过比较正常淋巴细胞与一名家族性高胆固醇血症(FH)患者淋巴细胞(该患者缺乏低密度脂蛋白(LDL)受体)的反应,研究了LDL受体在介导LDL免疫调节作用中的角色。用洛伐他汀(一种3-羟基-3-甲基戊二酰辅酶A还原酶的特异性抑制剂)阻断内源性固醇合成,并在缺乏脂蛋白的培养基中培养细胞,以补充LDL作为唯一胆固醇来源,以此证明LDL受体在支持淋巴细胞生长中的功能。洛伐他汀抑制正常和FH淋巴细胞有丝分裂原诱导的增殖。虽然被抑制酶的产物甲羟戊酸可克服这种抑制作用,但低浓度的LDL(小于10微克蛋白质/毫升)可恢复正常淋巴细胞而非FH淋巴细胞的反应。当正常和FH淋巴细胞在无洛伐他汀的情况下培养时,高浓度的LDL(大于100微克蛋白质/毫升)抑制有丝分裂原诱导的淋巴细胞增殖。对正常和FH淋巴细胞的抑制作用相似,即两者都需要相当高浓度的LDL,并且都可被转铁蛋白完全逆转。当正常淋巴细胞在补充转铁蛋白的无血清培养基中培养时,低浓度的LDL(小于10微克蛋白质/毫升)可显著增强增殖。相比之下,未观察到FH淋巴细胞生长增强。这些结果表明,无论内源性固醇生物合成是否存在,LDL介导的淋巴细胞生长增强都涉及LDL的特异性受体,而LDL引起的免疫抑制与这些受体无关。此外,结果表明外周淋巴细胞可用于评估受体介导的LDL摄取的功能完整性。